OmniAb Inc.
OABI evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for OABI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · OABI
OmniAb Inc. (OABI) is a biotechnology company that provides a proprietary transgenic animal platform (OmniAb®) for the discovery of fully human antibodies, generating revenue through partner licenses, milestones, and royalties.
Key risk: Dependence on partner success
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$649.9M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
OmniAb Inc. (OABI) is a biotechnology company that provides a proprietary transgenic animal platform (OmniAb®) for the discovery of fully human antibodies, generating revenue through partner licenses, milestones, and royalties.
- Cash & equivalents of $24.9M as of 2026-06-30 [sec].
- Total revenue of $13.4M for the six months ended 2026-06-30 [sec].
- Net loss of -$5.9M for the six months ended 2026-06-30 [sec].
- Shareholders' equity of $267.0M as of 2026-06-30 [sec].
- Revenue is expected to be driven by milestones and services in the shorter term and by royalties in the longer term [sec_mda · as of 2026-08-06].
What works
- The company tracks a growing number of partners and active programs, which it views as an indication of platform competitiveness and market penetration [sec_mda · as of 2026-08-06].
- Revenue is expected to be materially driven by milestones and services in the shorter term, and by royalties in the longer term, from partnered programs [sec_mda · as of 2026-08-06].
- The OmniAb platform has generated multiple active clinical programs and approved products, indicating downstream validation by partners [sec_mda · as of 2026-03-04].
What to weigh
- There is significant uncertainty in the timing and likelihood of reaching marketing authorization, and royalty payments may not become a material portion of revenue [sec_mda · as of 2026-08-06].
- The company does not control the progression, clinical development, regulatory strategy, or commercialization of partner programs, making it dependent on partners' efforts and decisions [sec_mda · as of 2026-08-06].
- Future capital requirements depend on factors such as partner success, expansion costs, and progress in selling platform access, which are uncertain [sec_mda · as of 2026-05-07].
From the filings
Quoted directly from source documents.
Revenue is expected to be driven by milestones and services in the shorter term and by royalties in the longer term.
“We believe our revenue will be materially driven by milestones and services in the shorter term, and by royalties in the longer term, from our partnered programs.”
SEC MD&A · August 6, 2026
There is significant uncertainty in the timing and likelihood of reaching marketing authorization.
“However, there is significant uncertainty in timing and likelihood of reaching marketing authorization in drug discovery and development, and we cannot be certain when, if at all, royalty payments will be a material portion of our revenue.”
SEC MD&A · August 6, 2026
The company is dependent on partners' efforts and decisions for program progression.
“Furthermore, we do not control the progression, clinical development, regulatory strategy or eventual commercialization of programs discovered using our platform, and as a result, we are dependent on our partners' efforts and decisions with respect to such programs.”
SEC MD&A · August 6, 2026
Active programs include clinical programs and approved products.
“Active clinical programs and approved products represents the number of unique programs for which an Investigational New Drug Application or equivalent under other regulatory regimes has been filed based on an OmniAb-derived antibody and which are in clinical development by our partners.”
SEC MD&A · March 4, 2026
Risks & what to watch (3)›
Key risks
- Dependence on partner success — Revenue and royalties depend on partners' ability to develop and commercialize therapies, which is outside OmniAb's control [sec_mda · as of 2026-08-06].
- Uncertain royalty timeline — Royalty payments may not become material due to uncertainty in marketing authorization timing and likelihood [sec_mda · as of 2026-08-06].
- Future capital needs — Capital requirements depend on uncertain factors like partner success and expansion costs; may need to raise additional capital [sec_mda · as of 2026-05-07].
What to watch
- Partner program progression and new license agreements, as they drive near-term milestones and services revenue [sec_mda · as of 2026-08-06].
- Clinical trial results and regulatory filings for OmniAb-derived antibodies in partner pipelines [sec_mda · as of 2026-03-04].
- Cash runway and any future capital raises, given the net loss and reliance on partner-dependent revenue [sec_mda · as of 2026-05-07].
Sources: SEC MD&A · Generated August 17, 2026 · How we verify sources →
Run OmniAb Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available OmniAb Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Profitable (positive operating cash flow)
D/E 0.12 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
0 buys · 3 sells (180d)
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
128
Total value held
$71.7M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 8,106,881 | $12.7M |
| vanguard capital management llc | 7,987,304 | $12.5M |
| cadian capital management, lp | 4,157,129 | $6.5M |
| geode capital management, llc | 2,925,579 | $4.6M |
| rice hall james & associates, llc | 2,547,255 | $4.0M |
| private management group inc | 2,429,166 | $3.8M |
| state street corp | 2,067,143 | $3.2M |
| dimensional fund advisors lp | 1,745,248 | $2.7M |
| towerview llc | 1,000,000 | $1.6M |
| charles schwab investment management inc | 959,573 | $1.5M |
Showing top 10 of 128 institutional holders of OmniAb Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 4.5%
- Days to cover
- 13.8
- Shares short
- 5,461,215
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
OABI short interestGovernance
Frequently asked questions
What is the AI investment thesis for OmniAb Inc.?
OmniAb Inc. (OABI) is a biotechnology company that provides a proprietary transgenic animal platform (OmniAb®) for the discovery of fully human antibodies, generating revenue through partner licenses, milestones, and royalties.
Who is the CEO of OmniAb Inc.?
Mr. Matthew W. Foehr is the chief executive officer of OmniAb Inc. (OABI).
Where is OmniAb Inc. headquartered?
OmniAb Inc. (OABI) is headquartered in EmeryVille, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.